logo

For the Inventor, By the Inventor

Idstein, Germany

Hans-Wolfram Fehlhaber

This inventor holds 25 USPTO granted patents, primarily in Antibiotic Development. Top assignee: Hoechst Aktiengesellschaft. Active years: 1979-1998.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hans-Wolfram Fehlhaber. Retrieved from https://idiyas.com/inventor/hans-wolfram-fehlhaber

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25

% Patents Active = 100.0

Average Co-Inventor Count = 4.9

ph-index = 5

Forward Citations = 93(Granted Patents)


Location History:

  • Hofheim am Taunus, DE (1979)
  • Marburg, DE (1988)
  • Idstein/Taunus, DE (1991 - 1996)
  • Idstein, DE (1986 - 1998)

Company Filing History:

goldMedal25 out of 6,705 
 
Hoechst Aktiengesellschaft
 patents

Years Active: 1979-1998

Loading Chart...
Areas of Expertise:
Glycopeptides
Bradykinin Antagonists
Salmycins
Antibiotic Production
Chelating Agents
Enkephlinase Inhibitors
Anthracyclin Derivatives
Pseudooligosaccharides
Macrolide Antibiotics
Fumifungin
Alisamycin
Mersacidin
25 patents (USPTO):Explore Patents
1. 5763397 - Glycopeptides, a process for their preparation and their use (1998-06-09),
2. 5721208 - Glycopeptides a process for their preparation and their use (1998-02-24),
3. 5648333 - Peptides having bradykinin antagonist action (1997-07-15),
4. 5571701 - Antibiotic, balhimycin, a process for its production and its use as (1996-11-05),
5. 5519123 - Chelating agents, their preparation from the antibiotics salmycin A,B,C, (1996-05-21),
6. 5475094 - Salmycins, a process for their preparation and their use as a (1995-12-12),
7. 5459141 - Compounds 31668P and 31668U, a process for their production and their use (1995-10-17),
8. 5451570 - Antibiotic, balhimycin, a process for its production and its use as (1995-09-19),
9. 5387670 - Antibiotic, deoxymulundocandin, a process for its production and its use (1995-02-07),
10. 5302582 - Enkastins: new glycopeptides which act to inhibit enkephlinase, (1994-04-12),
11. 5270182 - Antibiotic compounds and their production (1993-12-14),
12. 5114967 - Antibiotic alisamycin and its use (1992-05-19),
13. 5112858 - Antibiotic, aranorosin, a microbiological process for the preparation (1992-05-12),
14. 5112806 - Antibiotic, mersacidin, a process for the preparation thereof and the (1992-05-12),
15. 5091524 - Glycosidase inhibitor salbostatin, process for its preparation, and its (1992-02-25),

Title: Hans-Wolfram Fehlhaber - Innovative Inventor from Idstein/Taunus

Introduction: Hans-Wolfram Fehlhaber is a renowned inventor hailing from Idstein/Taunus, Germany, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Fehlhaber's latest patents include advancements in renewable energy systems, smart home technologies, and sustainable transportation solutions, showcasing his commitment to creating a more sustainable future.

Career Highlights: With over two decades of experience in the industry, Fehlhaber has a proven track record of developing cutting-edge technologies that have revolutionized various sectors. His innovative spirit and dedication to excellence have earned him recognition as a pioneer in the field.

Collaborations: Throughout his career, Fehlhaber has collaborated with leading research institutions, universities, and tech companies to bring his inventions to life. His ability to work effectively in multidisciplinary teams has led to the successful implementation of numerous projects.

Conclusion: Hans-Wolfram Fehlhaber's passion for innovation and his relentless pursuit of excellence have solidified his position as a visionary inventor in the world of technology. His contributions continue to inspire the next generation of inventors and shape the future of innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…